Experienced Leaders and Drug Developers

At TriGemX Bio, we focus on big health challenges that matter to patients and families. We are developing an effective, easy to use, well-tolerated agent addressing the needs of migraine patients.

Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, including a seasoned team with a proven track record of success.

Board of Directors

Cariad Chester

TCG Crossover

Jeff Goater

TriGemX Bio

Peter Hecht, Ph.D.

Tisento Therapeutics

William Rieflin

Independent

Amy Schulman

Polaris Partners

Peter Svennilson

The Column Group

Josh Wolfe

Lux Capital

Selected Investors